Imrecoxib vs. Celecoxib for Pain Control After Arthroscopic Knee Surgery .
Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study
Inflammopharmacology. 2022 Jun;30(3): 875-881.One hundred and twenty-six patients undergoing arthroscopic knee surgery were randomized in this non-inferiority trial to receive either imrecoxib (n=64) or celecoxib (n=62). The primary outcome of interest pain scores on a Visual Analog Scale (VAS), measured at rest and during movement up to 72 hours post-operation. Secondary outcomes of interest included pethidine administration, patient satisfaction, Lysholm scores, and the rate of adverse events. No significant differences were observed between the two groups in all outcomes: imrecoxib was found to be non-inferior to celecoxib for post-operative analgesia.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
